Cytori Therapeutics Inc (CYTX)

0.46
0.00 0.89
NASDAQ : Health Care
Prev Close 0.46
Open 0.46
Day Low/High 0.44 / 0.47
52 Wk Low/High 1.91 / 7.93
Volume 854.66K
Avg Volume 717.10K
Exchange NASDAQ
Shares Outstanding 32.48M
Market Cap 15.26M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cytori® Partners With MyTomorrows For Managed Access Program For Europe, Middle East And Latin America

Partnership to Launch at the EULAR (European League Against Rheumatism) Congress in Madrid, Spain June 14-17

Cytori Logs Final 48 Week Patient Follow Up Visit In Scleroderma Trial

Topline trial results announcement expected early Q3 2017

Cytori Provides Latest Corporate Update At The 18th Annual B. Riley & Co. Institutional Investor Conference

Presentation on Wednesday, May 24, 2017 at 09:00 AM Pacific Time

One Year Follow Up Of Cytori Cell Therapy™ In Investigator Erectile Dysfunction Trial

Data suggests safety and potential sustained efficacy in post prostatectomy patients  failing pharmacologic intervention

Cytori Therapeutics Stock Sliding on Offering Price Discount

Cytori Therapeutics Stock Sliding on Offering Price Discount

Cytori Therapeutics stock is sinking after the biotech company priced a stock offering at steep discount.

Cytori Provides Latest Corporate Update At The 2nd Annual Disruptive Growth & Healthcare Conference

Presentation on February 15, 2017 at 11:15 AM Eastern Time

GNC Plummets, Mallinckrodt Regains Ground Ahead of Market's Open

GNC Plummets, Mallinckrodt Regains Ground Ahead of Market's Open

Here's how biotech and healthcare stocks are moving ahead of market's open.

Cytori Therapeutics To Provide Corporate Update At 2017 Biotech Showcase™

Cytori Therapeutics To Provide Corporate Update At 2017 Biotech Showcase™

Presentation on January 10, 2016 at 4:00 PM Pacific Time

TheStreet Quant Rating: D- (Sell)